Sees FY24 revenue $58.5B-$61.5B, consensus $63.07B. Anticipates Approximately $8B in revenues for Comirnaty and Paxlovid. Seagen Expected to contribute approximately $3.1B of revenues.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now
- M & A News: Pfizer (NYSE:PFE) to Seal $43B Seagen Deal, Analyst Remains Upbeat
- Pfizer’s acquisition of Seagen receives all regulatory approvals
- Pfizer says FDA, EMA accept Marstacimab regulatory submissions
- Pfizer presents results from Phase 3 BASIS clinical trial